Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Antoine Hollebecque

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2869-7551; OpenAlex author ID A5086593040. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
80
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 6 papers · 2025: 4 papers · 2026: 5 papers

Papers 22

  1. Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment. Co-author DOI 10.1016/j.ejca.2025.116160↗
  2. Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. Co-author DOI 10.1016/j.ejca.2026.116227↗
  3. Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116768↗
  4. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2600752↗
  5. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  6. Molecular analysis highlights TREM2 as a discriminating biomarker for patients suffering from pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ctarc.2025.100939↗
  7. Precision medicine strategy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.esmoop.2025.105899↗
  8. Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patients. Last author DOI 10.1080/14796694.2025.2461442↗
  9. The Role of Computed Tomography-Determined Total Tumor Volume at Baseline in Predicting Outcomes of Patients with Locally Advanced Unresectable or Metastatic P… Last author DOI 10.3390/cancers18010020↗
  10. Clinical and molecular features of early onset pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.35135↗
  11. Codon-specific KRAS mutations predict survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2023.100030↗
  12. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2024.05.032↗
  13. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  14. Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study. Co-author DOI 10.1186/s12885-024-12016-z↗
  15. Role of molecular biology in the management of pancreatic cancer. Co-author DOI 10.4251/wjgo.v16.i7.2902↗
  16. The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients. Co-author DOI 10.1007/s10620-022-07733-z↗
  17. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2208470↗
  18. Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations. Co-author DOI 10.3390/biomedicines11092569↗
  19. FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? Co-author DOI 10.1016/j.ejca.2022.09.016↗
  20. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Co-author DOI 10.1136/jitc-2020-002068↗
  21. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Co-author DOI 10.1038/s41598-019-47489-7↗
  22. Systemic treatment of pancreatic cancer revisited. Co-author DOI 10.1053/j.seminoncol.2018.12.003↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michel Pierre Ducreux · 15 shared papers, 2019–2026 · strength 2.82
  2. Cristina Smolenschi · 14 shared papers, 2019–2026 · strength 2.62
  3. Alice Boilève · 12 shared papers, 2023–2026 · strength 2.33
  4. Anthony Tarabay · 11 shared papers, 2023–2026 · strength 2.13
  5. Antoîne Italiano · 5 shared papers, 2024–2026 · strength 0.90
  6. David Malka · 6 shared papers, 2019–2024 · strength 0.87
  7. Nathalie Lassau · 3 shared papers, 2025–2026 · strength 0.61
  8. Aurélien Lambert · 2 shared papers, 2024–2026 · strength 0.44
  9. Étienne Rouleau · 2 shared papers, 2023–2025 · strength 0.34
  10. Fanny Jaulin · 2 shared papers, 2024 · strength 0.30
  11. Thierry Conroy · 2 shared papers, 2019–2024 · strength 0.30
  12. Teresa Mercade Macarulla · 2 shared papers, 2021–2026 · strength 0.29
  13. Mélanie Debiais · 1 shared paper, 2026 · strength 0.25
  14. Matthieu Delaye · 1 shared paper, 2026 · strength 0.24
  15. Victor Robic · 1 shared paper, 2026 · strength 0.22
  16. Clara Helal · 1 shared paper, 2022 · strength 0.20
  17. Florent Ginhoux · 1 shared paper, 2025 · strength 0.20
  18. Camille Blériot · 1 shared paper, 2025 · strength 0.20
  19. Dimitrios Papakonstantinou · 1 shared paper, 2025 · strength 0.20
  20. Elissar Moujaess · 1 shared paper, 2025 · strength 0.19
  21. Roland Eid · 1 shared paper, 2025 · strength 0.19
  22. Wungki Park · 1 shared paper, 2026 · strength 0.19
  23. Hirokazu Shoji · 1 shared paper, 2026 · strength 0.19
  24. Makoto Ueno · 1 shared paper, 2026 · strength 0.19
  25. Anup Kasi · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.